Free Access
Med Sci (Paris)
Volume 29, Number 6-7, Juin–Juillet 2013
Page(s) 630 - 636
Section M/S Revues
Published online 12 July 2013
  1. Mazur MT, Clark HB. Gastric stromal tumors, reappraisal of histogenesis. Am J Surg Pathol 1983 ; 7 : 507–519. [CrossRef] [PubMed] [Google Scholar]
  2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 ; 279 : 577–580. [CrossRef] [PubMed] [Google Scholar]
  3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 ; 344 : 1052–1056. [CrossRef] [PubMed] [Google Scholar]
  4. Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012 ; 29 : 1765–1772. [CrossRef] [PubMed] [Google Scholar]
  5. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône-Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer 2010 ; 103 : 165–170. [CrossRef] [PubMed] [Google Scholar]
  6. Coindre JM, Emile JF, Monges G, et al. Tumeurs stromales gastro-intestinales: définition, caractéristiques histologiques, immunohistochimiques et génétiques, stratégie diagnostique. Ann Pathol 2005 ; 25 : 358–385. [CrossRef] [PubMed] [Google Scholar]
  7. Emile JF, Scoazec JY, Coindre JM. Tumeurs stromales gastrointestinales (GIST) : quoi de neuf en 2009 ? Ann Pathol 2009 ; 29 : 20–23. [CrossRef] [PubMed] [Google Scholar]
  8. Maas CP, ter Haar G, van der Gaag I, Kirpensteijn J. Reclassification of small intestinal and cecal smooth muscle tumors in 72 dogs: clinical, histologic, and immunohistochemical evaluation. Vet Surg 2007 ; 36 : 302–313. [CrossRef] [PubMed] [Google Scholar]
  9. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006 ; 30 : 90–96. [CrossRef] [PubMed] [Google Scholar]
  10. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008 ; 16 : 79–88. [CrossRef] [PubMed] [Google Scholar]
  11. Bachet JB, Emile JF. Diagnostic criteria, specific mutations and genetic predisposition in gastrointestinal stromal tumors (GISTs). Appl Clin Genet 2010 ; 3 : 1–17. [PubMed] [Google Scholar]
  12. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011 ; 35 : 1712–1721. [CrossRef] [PubMed] [Google Scholar]
  13. Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007 ; 31 : 113–120. [CrossRef] [PubMed] [Google Scholar]
  14. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006 ; 23 : 83. [Google Scholar]
  15. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012 ; 13 : 265–274. [CrossRef] [PubMed] [Google Scholar]
  16. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001 ; 411 : 355–365. [CrossRef] [PubMed] [Google Scholar]
  17. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 ; 299 : 708–710. [CrossRef] [PubMed] [Google Scholar]
  18. Emile JF, Théou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004 ; 2 : 597–605. [CrossRef] [PubMed] [Google Scholar]
  19. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007 ; 369 : 1731–1741. [CrossRef] [PubMed] [Google Scholar]
  20. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999 ; 59 : 4297–4300. [PubMed] [Google Scholar]
  21. Wardelmann E, Losen I, Hans V, et al. Deletion of Tryp-557 and Lys-558 in the juxtamembrane domaine of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003 ; 106 : 887–895. [CrossRef] [PubMed] [Google Scholar]
  22. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for sarcoma research (GEIS). J Clin Oncol 2005 ; 23 : 6190–6198. [CrossRef] [PubMed] [Google Scholar]
  23. Bachet JB, Hostein I, Le Cesne A, et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer 2009 ; 101 : 7–11. [CrossRef] [PubMed] [Google Scholar]
  24. Chibon F. Prédiction du risque métastatique dans les sarcomes : une nouvelle approche. Med Sci (Paris) 2011 ; 27 : 22–24. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  25. Lagarde P, Pérot G, Kauffmann A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012 ; 18 : 826–838. [CrossRef] [PubMed] [Google Scholar]
  26. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003 ; 21 : 4342–4349. [CrossRef] [PubMed] [Google Scholar]
  27. Théou N, Tabone S, Saffroy R, et al. High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors. Biochim Biophys Acta 2004 ; 1688 : 250–256. [CrossRef] [PubMed] [Google Scholar]
  28. Lasota J, vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007 ; 87 : 1029–1041. [CrossRef] [PubMed] [Google Scholar]
  29. Emile JF, Bachet JB, Tabone-Eglinger S, et al. GIST with homozygous KIT exon 11 mutations. Lab Invest 2008 ; 88 : 456–457. [CrossRef] [PubMed] [Google Scholar]
  30. Tabone-Eglinger S, Subra F, El Sayadi H, et al. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res 2008 ; 14 : 2285–2294. [CrossRef] [PubMed] [Google Scholar]
  31. Bougherara H, Subra F, Crépin R, et al. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 2009 ; 7 : 1525–1533. [CrossRef] [PubMed] [Google Scholar]
  32. Brahimi-Adouane S, Bachet JB, Tabone-Eglinger S, et al. Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT. Mol Oncol 2012 ; doi : pii: S1574-7891(12)00106-8. [Google Scholar]
  33. Bachet JB, Tabone-Eglinger S, Dessaux S, et al. Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples. PlosOne 2013 ; 8 : e61103. [Google Scholar]
  34. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008 ; 26 : 626–632. [CrossRef] [PubMed] [Google Scholar]
  35. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009 ; 373 : 1097–1104. [CrossRef] [PubMed] [Google Scholar]
  36. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010 ; 11 : 942–949. [CrossRef] [PubMed] [Google Scholar]
  37. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006 ; 24 : 4764–4774. [CrossRef] [PubMed] [Google Scholar]
  38. Kim EJ, Zalupski MM. Systemic theray for advanced gastrointestinal stromal tumors: Beyond Imatinib. J Surg Oncol 2011 ; 104 : 901–906. [CrossRef] [PubMed] [Google Scholar]
  39. Gastrointestinal stromal tumor meta-analysis group (MetaGIST. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010 ; 28 : 1247–1253. [CrossRef] [PubMed] [Google Scholar]
  40. Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012 ; 18 : 4458–4464. [CrossRef] [PubMed] [Google Scholar]
  41. Blay JY. Le futur des thérapeutiques ciblées en oncologie : trouver les cibles, traiter tôt et au long court. Med Sci (Paris) 2007 ; 23 : 1073–1074. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  42. Turhan A. L’imatinib mésylate : une révolution dans le traitement de la leucémie myéloïde chronique. Med Sci (Paris) 2003 ; 19 : 667–668. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  43. Favier J, Gimenez-Roqueplo AP. La génétique des paragangliomes et des phéochromocytomes. Med Sci (Paris) 2012 ; 28 : 625–632. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  44. Etienne G, Huguet F. Leucémie myéloïde chronique et thérapeutiques ciblées. Bientôt l’embarras du choix ? Med Sci (Paris) 2010 ; 26 : 911–914. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.